These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cancer immunotherapy targeting the CD47/SIRPα axis. Weiskopf K Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286 [TBL] [Abstract][Full Text] [Related]
8. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806 [TBL] [Abstract][Full Text] [Related]
9. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Matlung HL; Szilagyi K; Barclay NA; van den Berg TK Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703 [TBL] [Abstract][Full Text] [Related]
10. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716 [TBL] [Abstract][Full Text] [Related]
11. CD47/SIRPα axis: bridging innate and adaptive immunity. van Duijn A; Van der Burg SH; Scheeren FA J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032 [TBL] [Abstract][Full Text] [Related]
12. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells. Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154 [TBL] [Abstract][Full Text] [Related]
13. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Hsieh RC; Krishnan S; Wu RC; Boda AR; Liu A; Winkler M; Hsu WH; Lin SH; Hung MC; Chan LC; Bhanu KR; Srinivasamani A; De Azevedo RA; Chou YC; DePinho RA; Gubin M; Vilar E; Chen CH; Slay R; Jayaprakash P; Hegde SM; Hartley G; Lea ST; Prasad R; Morrow B; Couillault CA; Steiner M; Wang CC; Venkatesulu BP; Taniguchi C; Kim YSB; Chen J; Rudqvist NP; Curran MA Sci Immunol; 2022 Jun; 7(72):eabl9330. PubMed ID: 35687697 [TBL] [Abstract][Full Text] [Related]
14. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251 [TBL] [Abstract][Full Text] [Related]
15. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy. Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146 [TBL] [Abstract][Full Text] [Related]
16. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686 [TBL] [Abstract][Full Text] [Related]
17. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362 [TBL] [Abstract][Full Text] [Related]